1. Home
  2. STTK vs UHT Comparison

STTK vs UHT Comparison

Compare STTK & UHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Shattuck Labs Inc.

STTK

Shattuck Labs Inc.

N/A

Current Price

$4.55

Market Cap

474.6M

Sector

Health Care

ML Signal

N/A

UHT

Universal Health Realty Income Trust

N/A

Current Price

$37.17

Market Cap

525.1M

Sector

Real Estate

ML Signal

N/A

Company Overview

Basic Information
Metric
STTK
UHT
Founded
2016
1986
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Real Estate Investment Trusts
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
474.6M
525.1M
IPO Year
2020
1995

Fundamental Metrics

Financial Performance
Metric
STTK
UHT
Price
$4.55
$37.17
Analyst Decision
Strong Buy
Analyst Count
12
0
Target Price
★ $15.40
N/A
AVG Volume (30 Days)
★ 841.6K
86.6K
Earning Date
11-05-2026
10-27-2026
Dividend Yield
N/A
★ 7.82%
EPS Growth
★ 53.02
N/A
EPS
N/A
★ 1.14
Revenue
$1,000,000.00
★ $99,190,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$14.28
$6.18
P/E Ratio
★ N/A
$33.39
Revenue Growth
N/A
★ 0.18
52 Week Low
$1.89
$36.07
52 Week High
$8.33
$46.30

Technical Indicators

Market Signals
Indicator
STTK
UHT
Relative Strength Index (RSI) 36.78 43.57
Support Level $4.38 $37.36
Resistance Level $7.66 $42.08
Average True Range (ATR) 0.39 0.84
MACD -0.02 -0.06
Stochastic Oscillator 14.29 32.14

Price Performance

Historical Comparison
STTK
UHT

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

About UHT Universal Health Realty Income Trust

Universal Health Realty Income Trust is a healthcare REIT. The company is engaged in the business of investing in and leasing healthcare and human service facilities through direct ownership or through joint ventures, which aggregate into a single reportable segment. The company actively manages a portfolio of healthcare and human service facilities. The revenue and net income are generated from the operation of the investment portfolio, located throughout the United States.

Share on Social Networks: